2型生物标志物对哮喘诊断有帮助吗？
Are type-2 biomarkers of any help in asthma diagnosis?
作者信息
Nekoee Haleh, Graulich Emmanuel, Schleich Florence, Guissard Françoise, Paulus Virginie, Henket Monique, Donneau Anne Françoise, Louis Renaud
机构信息
Dept of Public Health, CHU Liege and University of Liege, Liege, Belgium.
Dept of Pneumology, CHU Liege and University of Liege, Liege, Belgium.
出版信息
ERJ Open Res. 2020 Jul 20;6(2). doi: 10.1183/23120541.00169-2020. eCollection 2020 Apr.
Abstract
摘要
https://bit.ly/3hYnnHu. （此为网址，一般保留原文不翻译）
相似文献
1
Are type-2 biomarkers of any help in asthma diagnosis?2型生物标志物对哮喘诊断有帮助吗？
ERJ Open Res. 2020 Jul 20;6(2). doi: 10.1183/23120541.00169-2020. eCollection 2020 Apr.
2
Using biomarkers to adjust corticosteroid dose in patients with severe asthma.使用生物标志物调整重度哮喘患者的皮质类固醇剂量。
Breathe (Sheff). 2021 Mar;17(1):200324. doi: 10.1183/20734735.0324-2020.
3
De-labelling severe asthma diagnosis: the challenge of DIPNECH.去除重度哮喘诊断标签：弥漫性泛细支气管炎伴机化性肺炎的挑战
ERJ Open Res. 2022 Feb 7;8(1). doi: 10.1183/23120541.00485-2021. eCollection 2022 Jan.
4
Is asthma a risk factor for COVID-19? Are phenotypes important?哮喘是新冠病毒病的一个风险因素吗？表型重要吗？
ERJ Open Res. 2021 Jan 25;7(1). doi: 10.1183/23120541.00216-2020. eCollection 2021 Jan.
5
Individual circadian preference (chronotype) is associated with asthma and allergic symptoms among adolescents.个体昼夜偏好（生物钟类型）与青少年的哮喘和过敏症状相关。
ERJ Open Res. 2020 Jul 6;6(2). doi: 10.1183/23120541.00226-2020. eCollection 2020 Apr.
6
Role of T2 inflammation biomarkers in severe asthma.T2炎症生物标志物在重度哮喘中的作用。
Curr Opin Pulm Med. 2016 Jan;22(1):59-68. doi: 10.1097/MCP.0000000000000231.
7
A survey of specialist opinions on biomarker use in severe asthma in Australia: scepticism but hope?澳大利亚关于生物标志物在重度哮喘中应用的专家意见调查：怀疑但仍有希望？
ERJ Open Res. 2020 May 26;6(2). doi: 10.1183/23120541.00113-2020. eCollection 2020 Apr.
8
(Oral) enoximone in asthma.（口服）依诺昔酮治疗哮喘
ERJ Open Res. 2020 Nov 2;6(4). doi: 10.1183/23120541.00319-2020. eCollection 2020 Oct.
9
Comparison of the Asthma Control Questionnaire and patient diaries in uncontrolled asthma.哮喘控制问卷与患者日记在未控制哮喘中的比较。
ERJ Open Res. 2023 May 22;9(3). doi: 10.1183/23120541.00104-2023. eCollection 2023 May.
10
NICE asthma guidelines: time to re-evaluate the diagnostic value of exercise challenge testing?英国国家卫生与临床优化研究所哮喘指南：是时候重新评估运动激发试验的诊断价值了吗？
ERJ Open Res. 2023 Mar 6;9(2). doi: 10.1183/23120541.00447-2022. eCollection 2023 Mar.
引用本文的文献
1
Biologics alter the relationship between exhaled nitric oxide fraction and sputum eosinophils in severe T2-high asthma patients.生物制剂改变了重度T2高哮喘患者呼出气一氧化氮分数与痰液嗜酸性粒细胞之间的关系。
ERJ Open Res. 2025 Jun 16;11(3). doi: 10.1183/23120541.00783-2024. eCollection 2025 May.
2
The carbon footprint of diagnostic delays in asthma.哮喘诊断延误的碳足迹。
ERJ Open Res. 2025 Feb 25;11(1). doi: 10.1183/23120541.00577-2024. eCollection 2025 Jan.
3
Fractional Exhaled Nitric Oxide Testing for the Diagnosis and Management of Asthma: a Health Technology Assessment.呼出气一氧化氮测定在哮喘诊断和管理中的应用：一项卫生技术评估。
Ont Health Technol Assess Ser. 2024 Jul 31;24(5):1-225. eCollection 2024.
4
Exhaled and Systemic Biomarkers to Aid the Diagnosis of Bronchial Asthma in Elite Water Sports Athletes.呼气和系统生物标志物有助于精英水上运动运动员的支气管哮喘诊断。
Med Sci Sports Exerc. 2024 Jul 1;56(7):1256-1264. doi: 10.1249/MSS.0000000000003419. Epub 2024 Mar 6.
5
Development and validation of a predictive model combining patient-reported outcome measures, spirometry and exhaled nitric oxide fraction for asthma diagnosis.一种结合患者报告结局指标、肺功能测定和呼出一氧化氮分数用于哮喘诊断的预测模型的开发与验证
ERJ Open Res. 2023 Feb 6;9(1). doi: 10.1183/23120541.00451-2022. eCollection 2023 Jan.
6
miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma.微小RNA-144-3p是一种与重度糖皮质激素依赖型哮喘相关的生物标志物。
Front Immunol. 2022 Apr 1;13:858722. doi: 10.3389/fimmu.2022.858722. eCollection 2022.
本文引用的文献
1
Bronchodilation Test with Inhaled Salbutamol Versus Bronchial Methacholine Challenge to Make an Asthma Diagnosis: Do They Provide the Same Information?吸入沙丁胺醇支气管舒张试验与支气管激发试验在哮喘诊断中的应用：二者提供的信息相同吗？
J Allergy Clin Immunol Pract. 2020 Feb;8(2):618-625.e8. doi: 10.1016/j.jaip.2019.09.007. Epub 2019 Sep 18.
2
Priorities for future research into asthma diagnostic tools: A PAN-EU consensus exercise from the European asthma research innovation partnership (EARIP).未来哮喘诊断工具研究的重点：欧洲哮喘研究创新伙伴关系（EARIP）的泛欧共识实践。
Clin Exp Allergy. 2018 Feb;48(2):104-120. doi: 10.1111/cea.13080.
3
Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.吸入性糖皮质激素在实际临床中对哮喘患者临床结局、痰液细胞及全身炎症的有效性：一项二级医疗中心的回顾性队列研究
BMJ Open. 2017 Nov 28;7(11):e018186. doi: 10.1136/bmjopen-2017-018186.
4
Exacerbation risk and characterisation of the UK's asthma population from infants to old age.从婴儿到老年，英国哮喘人群的恶化风险及特征。
Thorax. 2018 Apr;73(4):313-320. doi: 10.1136/thoraxjnl-2017-210650. Epub 2017 Oct 26.
5
After asthma: redefining airways diseases.哮喘之后：重新定义气道疾病。
Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11.
6
Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers?是否有可能使用生物标志物以足够的准确性判定或否定哮喘患者痰液嗜酸性粒细胞≥3%？
Respir Res. 2017 Jul 3;18(1):133. doi: 10.1186/s12931-017-0615-9.
7
Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma.成人医师诊断哮喘的再评估。
JAMA. 2017 Jan 17;317(3):269-279. doi: 10.1001/jama.2016.19627.
8
Accuracy of FENO for diagnosing asthma: a systematic review.呼出气一氧化氮检测诊断哮喘的准确性：系统评价。
Thorax. 2017 Feb;72(2):109-116. doi: 10.1136/thoraxjnl-2016-208704. Epub 2016 Jul 7.
9
Type 2 inflammation in asthma--present in most, absent in many.哮喘中的2型炎症——多数存在，许多不存在。
Nat Rev Immunol. 2015 Jan;15(1):57-65. doi: 10.1038/nri3786.
10
Biomarker-based asthma phenotypes of corticosteroid response.基于生物标志物的皮质类固醇反应性哮喘表型
J Allergy Clin Immunol. 2015 Apr;135(4):877-883.e1. doi: 10.1016/j.jaci.2014.10.026. Epub 2014 Dec 6.
Zotero 插件